Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

September 30, 2012

Conditions
LeukemiaHodgkin LymphomaNon-Hodgkin LymphomaMultiple MyelomaMyelodysplastic Syndrome
Interventions
DRUG

Clofarabine/Busulfan x 4

"Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"

PROCEDURE

Peripheral blood stem cell transplant

Peripheral blood stem cell transplant, after pre-conditioning drug treatment

RADIATION

Total Lymphoid Irradiation

Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant

Trial Locations (1)

48170

University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program, Ann Arbor

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT00556452 - Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | Biotech Hunter | Biotech Hunter